The sequel

Quote

anonymous

Guest
Same plot line. Not pulled before completing phase 3 though.

Did you see the highly, highly significant results? Highly. But clinically meaningful?

Which journal will be the winner?

Good luck
 












Can someone please explain to me why MV's picture is on LinkedIn associated with the ALZ result?
1. He had NOTHING to do with it (it was in-licensed before he even started)
2. Under his leadership BIIB has become a laughingstock in the industry

Does this company have ANY sense whatsoever????
 












CDR is virtually the same as Adu. 0.39 Vs. 0.45 after 18 months/ 36 infusions. This is a rounding error of efficacy. A 27% on CDR after 18 months when Adu had 22%
Micro hemorrhage at 17% Vs19 with Adu.
It’s statistically the same shitty MOA with a different name.
 






anonymous said:
CDR is virtually the same as Adu. 0.39 Vs. 0.45 after 18 months/ 36 infusions. This is a rounding error of efficacy. A 27% on CDR after 18 months when Adu had 22%
Micro hemorrhage at 17% Vs19 with Adu.
It’s statistically the same shitty MOA with a different name.
Click to expand...

Oh wow! Can I come back for my job again? NOT LOL
 
















































anonymous said:
CDR is virtually the same as Adu. 0.39 Vs. 0.45 after 18 months/ 36 infusions. This is a rounding error of efficacy. A 27% on CDR after 18 months when Adu had 22%
Micro hemorrhage at 17% Vs19 with Adu.
It’s statistically the same shitty MOA with a different name.
Click to expand...

Stop with the facts. With Rashid and Alisha, the marketing will ensure that is highly touted.

Higher efficacy than approved drugs in therapeutic class. Best in class.

Improved safety record for patients.

Demonstrated on diverse clinical trial patients with many comorbidities excluded by other companies

Wonder what happens when roche and lilly come in. May not be a win to be first again particularly with a pricing or data release misstep.
 






Biogen is desperate. Everything they’ve touched has gone wrong for the last 2+ years. This will be the Hail Mary, but the results aren’t good enough, and Adu tainted everything to come with this MOA. In short, they’re fucked. But, they’ll keep smiling and talking about all their amazing results and the success of the brand, right up until they cut people via video and start demanding sign-on bonuses back. New drug, but it will be the same, old Biogen.

For anyone who sees a job posted to promote Lec, ask for the bank. You’ll earn it.
 






New Alzheimer’s Drug Under Scrutiny For Cost, Patient Benefits | Kaiser Health News


https://khn.org/morning-breakout/new-alzheimers-drug-under-scrutiny-for-cost-patient-benefits/


The first "clearly successful clinical trial for a new Alzheimer's disease treatment in two decades," Stat notes, has brought intense scrutiny to the drug and Japanese maker Eisai. Renewed concerns over treatment costs, an investor "bonanza," and worries if it will really impact patients' lives are reported.
 












anonymous said:
With little data to go on, experts question how useful Eisai, Biogen’s new Alzheimer’s drug will be | BioPharma Dive


https://www.biopharmadive.com/news/lecanemab-alzheimers-patients-doctors-impact-eisai-biogen/632952/


A large study of the drug, called lecanemab, hit its main goal, but doctors and researchers point out the effects appear relatively modest.
Click to expand...

I’m sure Biogen was only charge 30-35k per year. They have to make up for the $900 MM settlement they just agreed to.
 












Drug very difficult to administer. Benefit - If any - takes months to appear. Brain bleeds still a significant problem. Clinical meaningfulness of any improvement questionable. Other than that, Mrs. Lincoln, how was the play?
 






Top Bottom
Back
Quote